7 Hills Pharma LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.7hillspharma.com
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1
Recruiting
- Conditions
- Pleural MesotheliomaRenal Cell CancerKidney CancerAnaplastic Lymphoma Kinase Genomic Tumor AberrationsALK Genomic Tumor AberrationsMelanomaAdvanced CancerMetastasisAdvanced Solid TumorSkin Cancer
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- 7 Hills Pharma, LLC
- Target Recruit Count
- 126
- Registration Number
- NCT06362369
- Locations
- 🇺🇸
Florida Cancer Specialists, Lake Mary, Florida, United States
🇺🇸Dartmouth Hitchcock, Lebanon, New Hampshire, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- Drug: 7HP349 Single Ascending DoseDrug: Placebo Single Ascending DoseDrug: Placebo Multiple Ascending DoseDrug: 7HP349 Multiple Ascending DoseDrug: 7HP349 Food Effect
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- 7 Hills Pharma, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT04508179
- Locations
- 🇺🇸
Frontage Clinical Services Inc., Secaucus, New Jersey, United States